LONDON (Thomson Financial) - Oxford BioMedica Plc. said Bavarian Nordic's
patent infringement suit in a U.S. court against Oxford BioMedica over three
patents relating to Modified Vaccinia Ankara (MVA) is without merit.
The gene therapy company said it is confident in its position, is fully
prepared to oppose the action vigorously, and "will seek all appropriate relief
against Bavarian Nordic".
Bavarian Nordic's claim is that the MVA vector system employed in Oxford
BioMedica's therapeutic cancer vaccine, TroVax, which is in clinical
development, infringes the three U.S. patents belonging to Bavarian Nordic.
The three patents correspond to Bavarian Nordic's European patent No.
1335987, "which is the subject of multiple oppositions, all asserting the
invalidity of the claimed technology", the company said.
Oxford BioMedica's senior vice president, commercial development, Peter
Nolan, said: "Throughout our 11 year history, Oxford BioMedica has been diligent
to ensure that it has freedom to operate for all its development programmes and
is entirely respectful of the intellectual property that has been developed by
others. We believe that Bavarian Nordic's claim is unwarranted and we have a
high degree of confidence that this action will prove fruitless for Bavarian
Nordic."
TFN.newsdesk@thomson.com
kal/cmr
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|